Ocular Therapeutix (OCUL) Change in Receivables (2013 - 2026)

Ocular Therapeutix's Change in Receivables history runs 14 years deep, the most recent figure standing at -$6.3 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 12.06% year-over-year to -$6.3 million in Q1 2026; TTM through Mar 2026 was -$874000.0, a 34.04% increase from a year earlier, with the FY2025 full-year figure at -$1.7 million, down 127.99% from the prior year.
• Change in Receivables fell to -$6.3 million in Q1 2026 per OCUL's latest filing, from -$118000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $6.2 million in Q2 2023 and bottomed at -$7.2 million in Q1 2025.
• The 5-year median for Change in Receivables is $356000.0 (2025), against an average of $188941.2.
• Biggest YoY gain for Change in Receivables was 11766.67% in 2025; the steepest drop was 2052.86% in 2025.
• Year by year, Change in Receivables stood at $1.5 million in 2022, then jumped by 70.06% to $2.6 million in 2023, then fell by 16.87% to $2.2 million in 2024, then tumbled by 105.48% to -$118000.0 in 2025, then slumped by 5241.53% to -$6.3 million in 2026.
• Per Business Quant, the three latest OCUL Change in Receivables figures stand at -$6.3 million (Q1 2026), -$118000.0 (Q4 2025), and $356000.0 (Q3 2025).